Accumulated Other Comprehensive Income (Loss), Net of Tax of Regulus Therapeutics Inc. from 31 Dec 2011 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Regulus Therapeutics Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD history and change rate from 31 Dec 2011 to 31 Mar 2025.
  • Regulus Therapeutics Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 31 Mar 2025 was $10,000.
Source SEC data
View on sec.gov
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

Regulus Therapeutics Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $10,000 +$55,000 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $50,000 +$50,000 31 Dec 2024 10-Q 08 May 2025 2025 Q1
Q3 2024 $120,000 +$120,000 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $87,000 -$87,000 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $45,000 -$45,000 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $0 +$12,000 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $0 +$31,000 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $0 +$36,000 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $0 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $12,000 -$12,000 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $31,000 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $36,000 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q4 2021 $0 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q4 2018 $0 +$134,000 31 Dec 2018 10-K 18 Mar 2019 2018 FY
Q3 2018 $63,000 +$41,000 +39% 30 Sep 2018 10-Q 09 Nov 2018 2018 Q3
Q2 2018 $80,000 +$8,000 +9.1% 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 $127,000 -$30,000 -31% 31 Mar 2018 10-Q 10 May 2018 2018 Q1
Q4 2017 $134,000 -$11,000 -8.9% 31 Dec 2017 10-K 18 Mar 2019 2018 FY
Q3 2017 $104,000 +$9,000 +8% 30 Sep 2017 10-Q 08 Nov 2017 2017 Q3
Q2 2017 $88,000 -$5,000 -6% 30 Jun 2017 10-Q 02 Aug 2017 2017 Q2
Q1 2017 $97,000 -$5,000 -5.4% 31 Mar 2017 10-Q 05 May 2017 2017 Q1
Q4 2016 $123,000 +$10,000 +7.5% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q3 2016 $113,000 +$21,000 +16% 30 Sep 2016 10-Q 02 Nov 2016 2016 Q3
Q2 2016 $83,000 +$72,000 +46% 30 Jun 2016 10-Q 03 Aug 2016 2016 Q2
Q1 2016 $92,000 +$71,000 +44% 31 Mar 2016 10-Q 03 May 2016 2016 Q1
Q4 2015 $133,000 +$64,000 +32% 31 Dec 2015 10-K 03 Mar 2017 2016 FY
Q3 2015 $134,000 -$68,000 -103% 30 Sep 2015 10-Q 06 Nov 2015 2015 Q3
Q2 2015 $155,000 -$113,000 -269% 30 Jun 2015 10-Q 05 Aug 2015 2015 Q2
Q1 2015 $163,000 -$104,000 -176% 31 Mar 2015 10-Q 08 May 2015 2015 Q1
Q4 2014 $197,000 -$181,000 -1131% 31 Dec 2014 10-K 23 Feb 2016 2015 FY
Q3 2014 $66,000 -$22,000 -50% 30 Sep 2014 10-Q 06 Nov 2014 2014 Q3
Q2 2014 $42,000 +$40,000 +49% 30 Jun 2014 10-Q 07 Aug 2014 2014 Q2
Q1 2014 $59,000 -$22,000 -59% 31 Mar 2014 10-Q 09 May 2014 2014 Q1
Q4 2013 $16,000 +$36,000 +69% 31 Dec 2013 10-K 19 Feb 2015 2014 FY
Q3 2013 $44,000 -$21,000 -91% 30 Sep 2013 10-Q 14 Nov 2013 2013 Q3
Q2 2013 $82,000 30 Jun 2013 10-Q/A 16 Aug 2013 2013 Q2
Q1 2013 $37,000 31 Mar 2013 10-Q 15 May 2013 2013 Q1
Q4 2012 $52,000 +$15,000 +22% 31 Dec 2012 10-K 28 Feb 2014 2013 FY
Q3 2012 $23,000 30 Sep 2012 10-Q 19 Nov 2012 2012 Q3
Q4 2011 $67,000 31 Dec 2011 10-K 19 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.